Martin S. Tallman
About
Martin S. Tallman is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health.
According to data from OpenAlex, Martin S. Tallman has authored 716 papers receiving a total of 34.8k indexed citations (citations by other indexed papers that have themselves been cited), including 505 papers in Hematology, 293 papers in Molecular Biology and 185 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Martin S. Tallman's work include Acute Myeloid Leukemia Research (430 papers), Acute Lymphoblastic Leukemia research (183 papers) and Retinoids in leukemia and cellular processes (171 papers). Martin S. Tallman is often cited by papers focused on Acute Myeloid Leukemia Research (430 papers), Acute Lymphoblastic Leukemia research (183 papers) and Retinoids in leukemia and cellular processes (171 papers). Martin S. Tallman collaborates with scholars based in United States, Israel and Canada. Martin S. Tallman's co-authors include Jacob M. Rowe, Elisabeth Paietta, Frederick R. Appelbaum, Richard A. Larson, Mark R. Litzow, Jacob M. Rowe, Peter H. Wiernik, Hillard M. Lazarus, Clara D. Bloomfield and John M. Bennett and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.
In The Last Decade
Martin S. Tallman
696 papers receiving 34.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Martin S. Tallman United States | 92 | 23.3k | 14.9k | 9.1k | 7.0k | 6.6k | 716 | 34.8k | ||
| Elihu H. Estey United States | 100 | 27.6k 1.2× | 16.0k 1.1× | 8.7k 1.0× | 8.7k 1.2× | 8.6k 1.3× | 687 | 39.7k | ||
| Pierre Fenaux France | 90 | 27.8k 1.2× | 15.7k 1.1× | 5.9k 0.7× | 11.4k 1.6× | 5.3k 0.8× | 869 | 36.8k | ||
| Frederick R. Appelbaum United States | 105 | 30.9k 1.3× | 9.8k 0.7× | 10.6k 1.2× | 8.9k 1.3× | 10.1k 1.5× | 595 | 42.6k | ||
| Bob Löwenberg Netherlands | 89 | 23.5k 1.0× | 14.3k 1.0× | 6.5k 0.7× | 5.9k 0.8× | 8.0k 1.2× | 534 | 35.9k | ||
| Farhad Ravandi United States | 90 | 24.8k 1.1× | 13.0k 0.9× | 9.3k 1.0× | 10.4k 1.5× | 7.5k 1.1× | 1.3k | 34.7k | ||
| Guillermo Garcia‐Manero United States | 106 | 30.6k 1.3× | 17.8k 1.2× | 8.3k 0.9× | 14.7k 2.1× | 7.5k 1.1× | 1.5k | 44.1k | ||
| Clara D. Bloomfield United States | 91 | 28.5k 1.2× | 17.7k 1.2× | 9.6k 1.1× | 12.1k 1.7× | 6.6k 1.0× | 406 | 42.9k | ||
| Miguel Á. Sanz Spain | 58 | 17.4k 0.7× | 8.5k 0.6× | 4.3k 0.5× | 4.3k 0.6× | 3.4k 0.5× | 486 | 22.5k | ||
| Stefan Faderl United States | 88 | 17.0k 0.7× | 8.2k 0.6× | 6.7k 0.7× | 10.9k 1.5× | 5.3k 0.8× | 570 | 27.0k | ||
| Charles A. Schiffer United States | 65 | 15.5k 0.7× | 6.8k 0.5× | 4.5k 0.5× | 6.5k 0.9× | 4.4k 0.7× | 280 | 22.0k |
Countries citing papers authored by Martin S. Tallman
Since
Specialization
Citations
This map shows the geographic impact of Martin S. Tallman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin S. Tallman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin S. Tallman more than expected).
Fields of papers citing papers by Martin S. Tallman
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Martin S. Tallman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin S. Tallman. The network helps show where Martin S. Tallman may publish in the future.
Co-authorship network of co-authors of Martin S. Tallman
This figure shows the co-authorship network connecting the top 25 collaborators of Martin S. Tallman. A scholar is included among the top collaborators of Martin S. Tallman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin S. Tallman. Martin S. Tallman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chin, Kuo‐Kai, Andriy Derkach, Christopher Famulare, et al.. (2024). HMA/VEN treatment modifications and associated outcomes in IDH -mutant AML. Leukemia & lymphoma. 66(2). 270–278.
2.
Bewersdorf, Jan Philipp, Martin S. Tallman, Christina Cho, Amer M. Zeidan, & Maximilian Stahl. (2020). Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis. Blood. 136(Supplement 1). 34–35.
3.
Choe, Sung, Hongfang Wang, Courtney D. DiNardo, et al.. (2019). Molecular Mechanisms Mediating Relapse Following Ivosidenib Monotherapy in Patients with IDH1-Mutant Relapsed or Refractory Acute Myeloid Leukemia. Blood. 134(Supplement_1). 545–545.
4.
Wendorff, Agnieszka A., S. Aidan Quinn, Marissa Rashkovan, et al.. (2018). Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL. Cancer Discovery. 9(3). 436–451.
5.
Amatangelo, Michael, Lynn Quek, Alan H. Shih, et al.. (2017). Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 130(6). 732–741.
6.
Goldberg, Aaron D., Martin S. Tallman, Melhem Solh, et al.. (2017). Results from an Ongoing Phase 1 Study Indicate ACDT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia. Blood. 130. 2662–2662.
7.
Meyer, Sara E., Tingting Qin, David E. Muench, et al.. (2016). DNMT3A Haploinsufficiency Transforms FLT3 ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia. Cancer Discovery. 6(5). 501–515.
8.
Park, Jae H., Baozhen Qiao, Katherine S. Panageas, et al.. (2011). Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood. 118(5). 1248–1254.
9.
McClune, Brian, Daniel J. Weisdorf, Tanya L. Pedersen, et al.. (2010). Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome. Journal of Clinical Oncology. 28(11). 1878–1887.
10.
Cripe, Larry D., Hajime Uno, Elisabeth Paietta, et al.. (2010). Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 116(20). 4077–4085.
11.
Döhner, Hartmut, Elihu H. Estey, Sergio Amadori, et al.. (2009). Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 115(3). 453–474.
12.
Kantarjian, Hagop M., Jörge E. Cortes, Dong‐Wook Kim, et al.. (2009). Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 113(25). 6322–6329.
13.
Figueroa, María E., Lucy Skrabanek, Yushan Li, et al.. (2009). MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 114(16). 3448–3458.
14.
DeMichele, Angela, Robert P. Gray, Jinbo Chen, et al.. (2009). Host Genetic Variants in the Interleukin-6 Promoter Predict Poor Outcome in Patients with Estrogen Receptor-Positive, Node-Positive Breast Cancer. Cancer Research. 69(10). 4184–4191.
15.
Flinn, Ian W., Donna Neuberg, Michael R. Grever, et al.. (2007). Phase III Trial of Fludarabine Plus Cyclophosphamide Compared With Fludarabine for Patients With Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997. Journal of Clinical Oncology. 25(7). 793–798.
16.
Goldstone, Anthony H., Susan Richards, Hillard M. Lazarus, et al.. (2007). In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 111(4). 1827–1833.
17.
Grever, Michael R., David Lucas, Gordon W. Dewald, et al.. (2007). Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997. Journal of Clinical Oncology. 25(7). 799–804.
18.
Sanz, Miguel Á., Martin S. Tallman, & Francesco Lo‐Coco. (2004). Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood. 105(8). 3019–3025.
19.
Goldstone, A H, Stephanie Richards, P H Wiernik, et al.. (1999). Philadelphia chromosome plus ve patients with adult acute lymphoblastic leukaemia (ALL), early results from the international ALL trial (MRC UKALL-XII/ECOG E2993).. Blood. 94.
20.
Tallman, Martin S.. (1994). All-trans-retinoic acid in acute promyelocytic leukemia and its potential in other hematologic malignancies.. PubMed. 31(4 Suppl 5). 38–48.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Elihu H. Estey Breakdown of academic impact, for papers by Pierre Fenaux Breakdown of academic impact, for papers by Frederick R. Appelbaum Breakdown of academic impact, for papers by Bob Löwenberg Breakdown of academic impact, for papers by Farhad Ravandi Breakdown of academic impact, for papers by Guillermo Garcia‐Manero Breakdown of academic impact, for papers by Clara D. Bloomfield Breakdown of academic impact, for papers by Miguel Á. Sanz Breakdown of academic impact, for papers by Stefan Faderl Breakdown of academic impact, for papers by Charles A. Schiffer